Background: Obesity is a known risk factor for wound complications; however, unlike elective upper extremity procedures, where obesity can be modified preoperatively, excision of soft tissue sarcomas (STSs) is not elective, and as such, obesity cannot be modified. There is a paucity of data concerning the impact of obesity on wound healing in upper extremity sarcoma surgery. 
Introduction
Advances in preoperative imaging, radiotherapy, and surgical techniques have allowed limb salvage surgery to become the treatment of choice for extremity soft tissue sarcomas (STSs). [1] [2] [3] [4] However, in the setting of limb salvage surgery, postoperative complications, namely, wound dehiscence and infection, are relatively common. [5] [6] [7] [8] [9] Due to the substantial patient morbidity associated with wound dehiscence and infection, the ability to identify risk factors for their development is vital for preoperative risk stratification.
Obesity (body mass index [BMI] ⩾30 kg/m 2 ), severe obesity (BMI = 35-39.9 kg/m 2 ), and morbid obesity (BMI ≥40 kg/m 2 ) are known risk factors for postoperative wound complications and infection in a variety of upper extremity orthopedic procedures. [10] [11] [12] [13] [14] Although an elevated BMI is strongly associated with wound complications and infection following these procedures, BMI is considered a "modifiable" risk factor. Compared with the elective shoulder arthroplasty patient population, where patients can take the time prior to undergoing surgery to lose weight, in the setting of a STS this is impossible. Once diagnosed with a STS, patients require relatively urgent surgical excision, with or without radiotherapy, to preserve their life and limb, and as such, the patients' BMI can no longer be considered "modifiable." Currently, there is a relative paucity of data examining the impact of obesity, severe obesity, and morbid 1 University of Toronto, ON, Canada 2 Mayo Clinic, Rochester, MN, USA obesity on the outcome of upper extremity limb salvage surgery for STS. The purpose of this study is to investigate the impact of obesity on the outcome of upper extremity limb salvage surgery with a focus on: (1) postoperative complications; (2) oncologic outcome; (3) rates of limb salvage; and (4) patient function.
Methods
Following institutional review board approval, we identified 290 patients from our institution's prospectively maintained database of patients undergoing resection and limb salvage of a STS of the shoulder girdle and upper extremity from 2006-2014. In this cohort, the BMI was not captured in 29 patients who were therefore excluded from the study. The remaining cohort (N = 261, Table 1 ; n = 5, 2%). 15 The most common resection locations were periscapular (n = 63, 24%) and deltoid (n = 40, 15%).
Radiotherapy was administered to 138 patients (53%) preoperatively and 12 patients (5%) postoperatively. The necessity for radiation was determined based on anticipated surgical margins and after multidisciplinary discussion at sarcoma tumor board. Preoperative radiotherapy was administered to patients over a 5-week period for a total dose of 50 Gy (25 fractions of 2 Gy). Surgical resection was then performed 4 to 6 weeks following completion of radiotherapy depending on the resolution of any skin reaction. Postoperative radiotherapy was administered over a 6-week period for a total dose of 66 Gy (33 fractions of 2 Gy) once the wound was deemed to be healed by the treating surgeon and radiation oncologist.
All surgical resections were performed by orthopedic oncology subspecialty surgeons. The margins were classified as negative (R0, n = 215, 82%) or microscopically positive (R1, n = 46, 18%). There were no cases of grossly positive tumor resections. The mean tumor size was 6 cm (range = 0.6-28 cm), and mean tumor volume was 313 cm 3 (range = 0.1-14 054 cm 3 ). The tumor was located deep to fascia in 138 (53%) patients. Tumor grade based on the Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC) scoring system, 16 included grade 1 (n = 88, 30%), grade 2 (n = 71, 24%), and grade 3 (n = 125, 43%). In 6 (2%) patients, the tumor could not be graded. One hundred seventy-three patients (66%) underwent primary tumor excision, while 65 (25%) were tumor bed re-excisions following a previous inadvertent sarcoma excision ("whoops" procedure) performed elsewhere, and 24 (9%) were re-excisions of a local recurrence following a previous incomplete excision at an outside institution. Most surgical wounds were closed primarily (n = 168, 64%), while 83 (32%) required a flap (58 rotational and 25 free), and 10 (4%) required a split-thickness skin graft. The mean operative time was 4 hours (range = 1-18 hours).
The tumor registry of our institution prospectively follows patients at regular intervals and specifically collects Note. Other: histiocytic sarcoma (n = 1), soft tissue Ewing sarcoma (n = 1), alveolar soft-part sarcoma (n = 1), hemangioendothelioma (n = 1), angiosarcoma (n = 1), clear cell sarcoma (n = 1), pleomorphic dermal sarcoma (n = 1), sclerosing liposarcoma (n = 1), dermatofibrosarcoma protuberans with secondary fibrosarcoma (n = 1).
the time and location of any tumor recurrence, amputation, additional surgical procedures, and death. Regular followup consisted of clinical examination and chest radiographs every 3 months for the first 2 years, every 6 months for 2 to 5 years, and annually for 5 to 10 years. To evaluate early and late complications, all surviving patients had at least 1 month of clinical follow-up, with a mean follow-up of 4 years (range = 1 month-10 years). Wound complications analyzed included wound dehiscence, delayed wound healing, or infection. A postoperative infection was defined as a wound which had the presence of gross purulence, cellulitis, or positive bacterial cultures.
Continuous variables were assessed using an unpaired Student t test (mean ± SE of mean), whereas categorical variables were compared with the Fisher exact test. Survival estimates were made using the Kaplan-Meier method. Cox proportional hazard regression analysis was performed to assess the risk of reoperation, wound healing complications, or postoperative infection. Multivariate analysis was not performed due to the limited number of events. Functional outcome was measured using the Musculoskeletal Tumor Society (MSTS) 1993 17 rating system and the Toronto Extremity Salvage Scores (TESS) 18 at each patient's last clinical follow-up. Mann-Whitney U tests were used to compare the mean scores between the patient cohorts for the TESS and MSTS scores. Statistical significance was set at a P value <.05.
Results

Cohort Comparison
In comparing obese with nonobese patients, there was no difference in the mean operative time (3.9 ± 0.3 hours vs 3.8 ± 0.2 hours, P = .84), mean tumor size (6.1 ± 0.6 cm vs 6.3 ± 0.3 cm, P = .69), proportion of high grade tumors (34% vs 41%, P = .32), tumors deep to the fascia (48% vs 54%, P = .39), need for flap coverage (32% vs 37%, P = .46), or use of neoadjuvant radiotherapy (49% vs 54%, P = .57) between cohorts.
Postoperative Complications
Following sarcoma resection, 49 patients (19%) sustained a wound dehiscence or delayed healing and infection. This included 27 patients (10%) with an isolated wound dehiscence or delayed wound healing, 12 (5%) sustained a combined wound dehiscence and infection, while 10 (4%) sustained an isolated wound infection. Forty-five patients (17%) sustained a wound dehiscence or infection within 30 days. Infections were located either superficial (n = 14, 5%) or deep (n = 8, 3%) to the fascia. These complications resulted in a repeated operative procedures in 33 (12%) patients, most commonly a debridement of a wound dehiscence (n = 20, 8%). Of these repeated procedures, 4 (2%) were due to free-flap failures.
In an analysis of risk factors for postoperative wound dehiscence and delayed wound healing (Table 2) , class III obesity (hazard ratio [HR] = 8.19, 95% confidence interval [CI] = 1.96-22.96, P < .001), operative time greater than 5 hours (HR = 3.17, 95% CI = 1.64-6.42, P < .001), and flap closure (HR = 2.82, 95% CI = 1.50-5.44, P < .001) were all significantly associated with an increased risk of the development of a wound dehiscence or delayed healing. Tobacco use (HR = 2.11, 95% CI = 0.97-4.21, P = .056) was strongly associated with wound dehiscence and delayed healing, however it failed to reach statistical significance.
In an analysis of risk factors (Table 2 ) for a postoperative infection (deep or superficial), class III obesity (HR = 10.14, 95% CI = 1.61-34.97, P = .01), preoperative radiotherapy (HR = 3.02, 95% CI = 1.19-9.21, P = .01), and tumors deep to fascia (HR = 3.14, 95% CI = 1.24-9.58, P = .01) significantly increased the risk for the development of a postoperative infection. Tumor volume greater than 300 cm 3 (HR = 2.42, 95% CI = 0.96-5.75, P = .06) was strongly associated with infection, however failed to reach statistical significance.
In an analysis of risk factors for a repeated surgical procedure to manage a wound complication or infection (Table  2) , operative time greater than 5 hours (HR = 3.75, 95% CI = 1.82-8.28, P = .003) and flap closure (HR = 3.39, 95% CI = 1.69-7.12, P < .001) were both significantly associated with an increased risk for a repeated procedure. Class III obesity (HR = 5.12, 95% CI = 0.82-16.98, P = .07) and distal extremity resections (HR = 1.93, 95% CI = 0.93-3.84, P = .07) were strongly associated with a need for a repeated surgical procedure, however failed to reach statistical significance.
Oncologic Outcome
Following upper extremity limb salvage, 47 patients (16%) expired at a mean of 2 years (range = 3 days-6 years) postoperatively. Patients with obesity (HR = 0.60, 95% CI = 0.26-1.23, P = .17) and morbid obesity (HR = 1.54, 95% CI = 0.08-7.06, P = .68) were not at increased risk for mortality following upper extremity limb salvage surgery. The overall 2-, 5-, and 10-year survival following upper extremity limb salvage surgery was 88%, 79%, and 76%.
Disease recurrence occurred in 61 patients (23%) at a mean of 2 years (1 month-7 years) postoperatively. Disease recurrence was classified as distant (n = 45, 16%), local (n = 11, 4%), and concurrent local and distant (n = 5, 2%). Obesity was not associated with local recurrence (HR = 0.68, 95% CI = 0.15-2.14, P = .48) or the development of metastatic disease (HR = 0.95, 95% CI = 0.47-1.78, P = .89). Of the risk factors analyzed, a positive surgical margin (HR = 4.45, 95% CI = 1.58-11.96, P = .005) and operative time greater than 5 hours (HR = 2.85, 95% CI = 1.01-9.19, P = .04) was associated with an increased risk of local tumor recurrence (Table 3 ). There was no difference in the proportion of patients with a positive surgical margin between obese and nonobese patients (19% vs 17%, P = .71). Risk factors for distant disease recurrence were related to tumor characteristics and included high grade tumors (HR = 3.68, 95% CI = 1.99-7.24, P < .001), tumor size greater than 5 cm (HR = 3.12, 95% CI = 1.65-6.40, P < .001), tumor volume greater than 300 cm 3 (HR = 2.62, 95% CI = 1.44-4.64, P < .001), tumors deep to the fascia (HR = 2.47, 95% CI = 1.37-4.66, P = .002), operative time greater than 5 hours (HR = 2.27, 95% CI = 1.27-4.13, P = .005), and preoperative radiotherapy (HR = 2.00, 95% CI = 1.10-3.84, P = .02).
There were 2 late amputations that occurred at 1 and 3 years postoperatively, both due to local tumor recurrence of high grade myxofibrosarcoma. At 10 years postoperatively, the overall limb salvage rate was 99%. Obesity (HR = 2.63, 95% CI = 0.10-66.50, P = .50) was not associated with an increased risk of amputation.
Functional Outcome
Following lower extremity limb salvage surgery, the mean TESS and MSTS93 scores were 91 (range = 40-100) and 94 (range = 57-100), respectively. There was no difference in the mean TESS (93 vs 90, P = .13) or MSTS93 (95 vs 93, P = .40) scores between obese and nonobese patients.
Discussion
Obesity is an established risk factor for wound complications and infection, yet is considered modifiable for a majority of elective orthopedic procedures. Unlike an elective orthopedic procedure, upper extremity limb salvage surgery for STS is a nonelective procedure, and the impact of obesity on outcome is relatively underreported. The results of this study show that morbid obesity substantially increases the risk of developing postoperative wound complications and infection following resection of an upper extremity STS.
Previous studies have examining the risk factors for wound complications and infection following limb salvage surgery have mainly focused preoperative radiotherapy, tumor size, location, and need for flap coverage, [4] [5] [6] [7] 9, [19] [20] [21] [22] [23] [24] with few series examining the impact of obesity on the outcome of upper extremity limb salvage surgery. [6] [7] [8] [9] 25 When series have tried to focus on the impact of obesity, they have been flawed by combining the upper and lower extremity patients into a single cohort and noting no difference in the rate of wound complications, 25 or only finding differences in patients undergoing flap coverage. 9 In the current series, class III obesity was noted to be an independent risk factor for postoperative wound complications and infection in all patients following resection of an upper extremity STS, which has not been previously reported.
Tumor size and the use of preoperative radiotherapy have been shown in several sarcoma studies to increase the risk of postoperative wound complications. [4] [5] [6] [7] 9, [20] [21] [22] O'Sullivan et al 4 noted an overall increased risk of postoperative wound complications in the entire preoperatively HAND 14 (1) treated radiotherapy group. However, of the 18 patients with an upper extremity STS in that study, only 1 (6%) had a postoperative wound complication compared with 43% of patients with a lower extremity STS. As the upper extremity sarcoma surgery has historically not been associated with an increased risk of wound complication and infection when compared with the lower extremity, physicians may underestimate the risk of complications for their patients.
The results of the current series show that when compared with other patients undergoing surgical excision of an upper extremity sarcoma, patients with class III obesity have the highest risk of wound complications and infection, and should be cautioned on this independent risk factor. Morbid obesity and super (BMI ⩾50 kg/m 2 ) obesity have been significantly associated with wound complications following total joint arthroplasty. [10] [11] [12] [13] [14] [26] [27] [28] [29] [30] For elective lower extremity arthroplasty patients, the American Association of Hip and Knee Surgeons stated that the risk of postoperative complications outweighs the benefits of total joint arthroplasty in the morbidly obese and super obese patient populations. The increasing complication profile of these patient populations increases the burden on the health care system and has a substantial negative impact on many of these procedures. In a recent study examining obesity as a continuous variable in the outcome of shoulder arthroplasty, the authors noted an increase in complications, with a pronounced increase in the morbidly obese patient population. 13 Unlike patients undergoing an elective arthroplasty procedure, in the setting of STS, they are unable to take the time necessary to lose weight to reduce the risk of complications, thereby making obesity a nonmodifiable risk factor. The results of this study indicate that morbid obesity (class III) is an independent risk factors for wound dehiscence and infection, and as such should be considered a nonmodifiable in terms of their effect on postoperative complications following upper extremity STS resection. In an attempt to reduce the risk of infection and wound dehiscence following upper extremity limb salvage surgery, we recommend optimizing other potentially modifiable risk factors (diabetes mellitus, cardiovascular disease, and malnutrition) prior to STS resection in an attempt the risk of postoperative complications. 31, 32 The findings of this study should be taken in light of certain limitations. Although the study was performed retrospectively, the data were collected in a prospective fashion using our tumor registry which may help reduce recall bias. Although, compared with previous studies examining upper extremity STS, this investigation assessed a larger patient population, in general the sample size could still be considered small, as such this study could be limited by beta error. In addition, we are unable to comment on variables not collected by the registry or patient records such as diabetes or cardiovascular disease, which limits the analysis we are able to perform. It is possible these variables not analyzed in our study are significant risk factors for the development of postoperative wound complications and infection, and as such could substantially impact the outcome of the study. Although the surgical resections were performed by fellowship-trained orthopedic oncologists, each resection was different. Currently, there is not a standardized protocol for use of flap coverage and wound closure; however, for a majority of STS patients, the treatment is fairly unified and involves a combination of preoperative radiotherapy followed by resection. Unlike previous reports, the result of the current series identifies morbid obesity as independent risk factors for the development of postoperative wound dehiscence and infection following excision of an upper extremity soft tissue sarcoma. Unlike patients undergoing an elective orthopedic procedure, delaying surgery for weight loss in the setting of a soft tissue sarcoma is impossible, and as such, morbid obesity should be considered nonmodifiable risk factors for the development of these complications following upper extremity STS resection. Given the increased risk associated with class III obesity, risk stratification models should include this and not penalize surgeons for taking on these complex cases.
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